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Huisgen [3+2] dipolar cycloaddition of 60 0-azido-60 0-deoxy-a-galactosyl ceramide 11 with a range of
alkynes (or a benzyne precursor) yielded a series of triazole-containing a-galactosyl ceramide (a-GalCer)
analogues in high yield. These a-GalCer analogues and the precursor azide 11were tested for their ability
to activate iNKT cells and stimulate IL-2 cytokine secretion in vitro, and IFN-c and IL-4 cytokine secretion
in vivo. Some of these analogues, speciﬁcally 11, 12b, 12f and 13, were more potent IL-2 stimulators than
the prototypical CD1d agonist, a-GalCer 1. In terms of any cytokine bias, most of the triazole-containing
analogues exhibited a small Th2 cytokine-biasing response relative to that shown by a-GalCer 1. In con-
trast, the cycloaddition precursor, namely azide 11, provided a small Th1 cytokine-biasing response.
 2012 Elsevier Ltd. Open access under CC BY license.O
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1   R = (CH2)24CH3, n = 13, X = O (KRN7000)
3   R = (CH2)6CH3, n =13, X= O
4   R = (CH2)22CH3, n = 4, X = O (OCH)
5   R = (Z, Z )-(CH2)9(CH=CHCH2)2(CH2)3CH3
n =13, X = O
6   R = (CH2)24CH3, n = 13, X = CH2 (α-C-GalCer)
Figure 1. Prototypical KRN7000 (1), naturally occurring AGL-9b (2) and biologically
active analogues 3–6.a-GalCer (KRN7000, 1, Fig. 1) is a simpliﬁed synthetic analogue
of the naturally occurring agelasphins (including AGL-9b, 2, Fig. 1),
which were isolated from the marine sponge Agelas mauritianus.1
a-GalCer has become the prototypical ligand for studying the
CD1d-restricted activation of invariant Natural Killer T cells (iNKT
cells).2 CD1d is an MHC-like protein located on the surface of
various antigen-presenting cells, including dendritic cells and mac-
rophages.3 a-GalCer (1) binds through its two long lipid chains into
two deep hydrophobic pockets of the CD1d molecule, to form an
a-GalCer–CD1d complex.4 CD1d then presents this glycolipid to
T-cell receptors (TCRs) located on iNKT cells, an event which elicits
an immune response through the release of both pro-inﬂammatory
(Th1 (IFN-c)) and regulatory (Th2 (IL-4)) cytokines.5,6 The release
of Th1 cytokines is associated with antitumour and antimicrobial
functions,7 whilst the release of Th2 cytokines is implicated in
alleviation of autoimmune diseases8–10 such as multiple sclerosis11
and arthritis.12 When both Th1 and Th2 cytokines are released
together, however, their effects are counteractive, providing
unpredictable biological effects.13 The absence of a Th1/Th2 cyto-
kine bias has hindered the therapeutic application of a-GalCer
and encouraged the search for analogues of this CD1d agonist,
which induce a more biased Th1/Th2 response.14 Most modiﬁca-
tions to a-GalCer have been to the ceramide portion of the mole-
cule and some important examples are shown in Figure 1. ForY license.example, truncation of either the fatty acid chain (3)15 or the
sphingosine chain (OCH, 4)16 produces a Th2 cytokine-biasing re-
sponse. A Th2 cytokine-biasing response is also observed when
unsaturation is incorporated into the acyl chain (a-GalCer C20:2,
5).17 Switching the anomeric oxygen atom for a methylene group
(a-C-GalCer, 6) provides an example of a Th1-skewing analogue.18
Despite the efforts of many laboratories, the factors which deter-
mine the nature and extent of any cytokine bias remain only par-
tially understood.19
The design of many glycolipid analogues has been guided by the
published crystal structures of the CD1d–KRN7000 complex and
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Figure 3. A route to 6-N-derivatised a-GalCer analogues, which allows late-stage
modiﬁcation of both the 6-N-substituent and the fatty acid group of the ceramide.
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veal the hydroxyl group at the 6-position of the sugar head-group
is the only hydroxyl group that is not directly involved in hydrogen
bonding to the CD1d protein or the TCR of the iNKT cell. As such,
a-galactosyl ceramides in which the hydroxyl group at the
6-position of the sugar head group has been modiﬁed, have
become attractive synthetic targets. Indeed, many groups have
shown that the TCR–glycolipid–CD1d interaction is tolerant to
derivatisation at this position of the molecule.22,23 For example,
Tashiro et al. found that methyl ether 7 (RCAI-61) skews the
cytokine proﬁle towards a Th1 response.22a The activity of 7 has
been rationalised by the methylation disrupting a hydrogen bond
between the oxygen atom of the 40 0-hydroxyl group and the hydro-
gen atom of the 60 0-hydroxyl group, thus rendering the 40 0-hydroxyl
group more available for TCR recognition.22a
The incorporation of nitrogen-containing functionalities into
the 6-position of the sugar has also proven to be worthwhile.23
From a practical point of view, incorporating a nitrogen functional-
ity into this position of the glycolipid serves to increase substrate
solubility (a-GalCer is very poorly soluble in most organic solvents
and water), facilitating easier synthesis, puriﬁcation, handling and
biological administration.23a More importantly, this type of struc-
tural change has also been shown to produce desirable biological
effects. For example, Trappeniers et al. have shown that analogues
containing aryl amides and ureas at the 60 0-position (e.g., 8 and 9)
can skew the cytokine proﬁle in favour of a Th1 cytokine respon-
se.23b A crystal structure of the CD1d–9–TCR complex reveals the
urea substituent residing in a hydrophobic pocket, effectively pro-
viding an extra site for binding. In addition, the naphthyl ring of 9
is likely to be involved in p–p stacking with the electron-rich in-
dole ring of the proximal Trp153.23c Interestingly, when the 6-ami-
do group is linked to a poly(ethylene glycol) chain, as in amide
analogue 10, the cytokine proﬁle is reversed such that a Th2-bias-
ing cytokine response is now observed (Fig. 2).23c
We have recently developed a synthesis of a 60 0-azido-60 0-
deoxy-a-galactosyl ceramide (11), which is a useful precursor for
the synthesis of 60 0-N-derivatised a-GalCer analogues ( Fig. 3).24
Reducing the azide functionality provides the corresponding
amine, potentially allowing ready access to amides, sulfonamides,
ureas, thioureas and secondary amines. Azide 11 is also primed for
more direct modiﬁcation utilising click chemistry.25–27
Alkyne–azide [3+2] dipolar cycloaddition reactions are highlyO
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Figure 2. Biologically active 60 0-derivatised a-galactosyl ceramide analogues 7–10.chemoselective, and we predicted that azide 11 should react read-
ily without the need to protect the hydroxyl groups, providing
ready access to a library of 1,2,3-triazole-containing KRN7000
derivatives from the large range of inexpensive, terminal alkynes
that are available.
1,2,3-Triazoles are considered to be non-hydrolysable bioisos-
teres of the amide bond.28a,29 In terms of atom positioning, the
1,4-disubstituted 1,2,3-triazole mimics the s-cis amide rotamer,
whilst the 1,5-disubstituted analogue mimics the s-trans amide
rotamer.28b The similarities and differences in hydrogen bonding
of these isosteres have been described recently by Tron et al.28b
Both 1,4- and 1,5-disubstituted triazoles can be accessed by judi-
cious choice of reagents and reaction conditions.25–27
As part of a wider programme directed towards generating CD1d
agonists,30 and to test the scope of azide 11 as a cycloaddition part-
ner, we embarked on the preparation of a range of 60 0-triazole-
substituted a-GalCer analogues. In the ﬁrst instance, we focused
on the 1,4-disubstitution pattern of the triazole, which was ac-
cessed via copper-catalysed click chemistry.25,26 Heating equimolar
quantities of azide 11with different acetylenes of varying steric de-
mand and hydrophilicity, in the presence of CuSO4 and sodium
ascorbate, provided the desired 1,4-disubstituted triazoles 12a–f
in excellent yields. In order to assess the effect of regiochemistry
on the biological activity, we were also keen to access the alterna-
tive regioisomer of triazole 12a.27 To this end, heating azide 11with
phenyl acetylene in the presence of 5 mol % Cp⁄Ru(PPh3)2Cl, pro-
vided 1,5-disubstituted triazole 13 in 78% yield. This ruthenium
catalyst is also reported to mediate the reaction with internal
alkynes and indeed, employing diphenyl acetylene yielded the
1,4,5-trisubstituted triazole 14 in 72% yield.27 Finally, benzotria-
zole-containing analogue 15 was also prepared in 69% yield from
an in situ-generated benzyne intermediate, by treating azide 11
with 2-(trimethylsilyl)phenyl triﬂuoromethanesulfonate in the
presence of TBAF (Scheme 1).31
a-GalCer analogues 11, 12a–f and 13–15 were initially tested
in vitro for their ability to stimulate IL-2 production by murine
iNKT hybridoma cells (Fig. 4).19 Analogues 11, 12b, 12f and 13were
all more active than a-GalCer 1, whilst the remaining analogues
tested displayed signiﬁcantly reduced activity relative to a-GalCer.
There were interesting differences in activity between the benzene
ring-containing analogues, in that triazole 13, which contains the
1,5-disubstitution pattern on the triazole ring, was far more active
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Scheme 1. Synthesis of triazole-containing a-GalCer analogues.32
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Figure 4. EC50 measurements using mouse iNKT hybridoma DN3A4–1.2. Top panel:
Glycolipids were titrated over3 log range and IL-2 levels at 24 h were measured in
culture supernatant by ELISA. After nonlinear curve ﬁtting, the glycolipid concen-
tration giving 50% maximum y-values was estimated. The horizontal dotted line is
the approximate 50% maximum response for the assay, and the vertical dashed
lines show the extrapolation to the x-axis values for determination of EC50.
Representative examples are shown for three glycolipid antigens, including the
positive control KRN7000 (1). Bottom panel: Relative potencies for all compounds,
based on 1/EC50 values as determined using mouse iNKT hybridoma DN3A4–1.2
and the method for measuring of EC50 values as described above.19
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Figure 5. IL-4 (top panel) and IFN-c (bottom panel) secretion after intraperitoneal
injection of a-GalCer 1, a-GalCer (C20:2) 5, 11, 12a–f and 13–15 in mice.33
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and benzotriazole 15. There is also a striking difference in activity
between the alkyl-substituted triazoles, with triazole 12b being far
more active than triazole 12c, despite only a four-carbon difference
in alkyl chain length between these two molecules.
a-GalCer analogues 11, 12a–f, 13–15 were next tested for their
ability to stimulate cytokine production in vivo by measuring the
serum IL-4 and IFN-c levels, at 2 h and 24 h, respectively, in
C57BL/6mice following intraperitoneal injection (Fig. 5).33 In terms
of overall cytokine release, all the analogues tested were active
in these in vivo experiments, with triazole 13 (containing the
1,5-disubstitution pattern) providing the highest levels of IL-4
secretion, and azide 11 providing the highest level of IFN-c secre-
tion. Again, there are interesting differences in the amount of cyto-
kine production elicited by the two alkyl-substituted analogues
(12b and 12c). Triazole 12b (containing an octyl chain) provides
more than double the amount of both IL-4 and IFN-c cytokines than
does triazole 12c (containing a dodecyl chain). That a relatively
small change to the length of the alkyl chain attached to the triazole
unit is having a large effect on the levels of cytokine production,
might be indicative of the amount of space available within an extra
hydrophobic binding site. Triazole 12f (containing a PEG-8 substi-
tuent), which contains a much longer (but hydrophilic) chain
length, elicits higher levels of cytokine production than both 12b
and 12c, providing similar results to a-GalCer in both the IL-4 andIFN-c assays. The ethylene glycol chain might not be expected to
beneﬁt from the presence of an extra hydrophobic binding site,
but might instead exert its effects on activity through increased
solubility.
Figure 6. IFN-c:IL-4 ratios for a-GalCer 1, a-GalCer (C20:2) 5, 11, 12a–f and 13–15
in mice. Normalised so that the value for a-GalCer (C20:2) 5 is 1.
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the ratio of IFN-c to IL-4 secretion was calculated and compared
with that for a-GalCer 1 (Fig. 6). Interestingly, analogues 12a and
13, which might be considered bioisosteric to the Th1-skewing
amide 8 and urea 9, were found instead to possess a small Th2
cytokine-biasing response, relative to a-GalCer. In fact, all of the
triazole-containing analogues showed either a small Th2 cyto-
kine-biasing response (being most pronounced in the case of ben-
zotriazole 15) or were similar in their behaviour to a-GalCer. The
only Th1-biasing analogue tested was the synthetic precursor of
our triazole analogues, namely azide 11. Triazole 12f, which might
have been expected to be a Th2 cytokine-biasing analogue owing
to its structural similarities with the Th2 cytokine-biasing amide
10, exhibited no signiﬁcant cytokine bias relative to a-GalCer.
In summary, click reactions of azide 11 with various alkynes
provided a library of 60 0-triazole-substituted a-GalCer analogues.34
The ability of these analogues to stimulate the production of IL-2
varied signiﬁcantly with small changes to the nature of the triazole
substituent. All of these new triazole-containing a-GalCer ana-
logues stimulated both IL-4 and IFN-c secretion in vivo, and elic-
ited either a small Th2 cytokine-biasing response or were similar
in their cytokine proﬁle to a-GalCer. The click chemistry precursor,
azide 11 was also tested, and found to provide a small Th1 cyto-
kine-biasing response. These initial biological results suggest that
subtle structural changes to this part of a-GalCer can have a signif-
icant effect on the observed cytokine bias. Future work will involve
further SAR studies and the use of computer modelling in order to
better understand how these molecules interact with the CD1d
molecule and the iNKT-cell TCR.
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